Crocs, Inc. vs Johnson & Johnson — how do they compare? Crocs, Inc. trades at $131.61 (market cap $6.63B), while Johnson & Johnson trades at $259.44 (market cap $630.94B). The key difference: Johnson & Johnson is far larger — about 95.2× Crocs, Inc.'s market cap, and Johnson & Johnson pays a 2.05% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals.
| CROX | JNJ | |
|---|---|---|
Market Cap | $6.63B | $630.94B |
Sector | Consumer Staples | Health |
52-Week High | $141.19 | $267.24 |
52-Week Low | $73.39 | $172.78 |
Enterprise Value | $8.14B | $659.21B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.05% |
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $136.62, up 1.82% with strong technical momentum and bullish moving averages. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $4.55 exceeding expectations. Despite a net loss in 2025 due to tax impacts, profitability metrics remain robust with 57.47% gross margins and 42.3% ROE. Recent news highlights tax strategy scrutiny but also strong DTC growth and raised 2026 guidance.
The stock presents value with a 12.12 P/E ratio below industry averages, supported by analyst consensus of $140.43 price target. Key risks include HEYDUDE brand weakness, tariff pressures, and ongoing tax scrutiny. Upside potential exists from international expansion and direct-to-consumer growth, though near-term volatility may persist around earnings.
Johnson & Johnson (JNJ) trades at $259.24, up 0.88% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $282.33. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The company maintains strong profitability, including a 67.91% gross margin and 21.48% net income margin, supported by consistent dividend payments, including a recent $1.34 per share payout.
JNJ offers stability with a 64-year dividend growth streak and robust fundamentals, but risks include rising debt-to-asset ratios (24.06% in 2025) and sector volatility. Upside potential hinges on execution of growth initiatives and healthcare market dynamics, with analysts favoring a buy rating (52.5% consensus).
Trailing returns across standard periods
Latest headlines on both assets
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →